Aura Biosciences Appoints New Director, Adjusts Executive Pay
Ticker: AURA · Form: 8-K · Filed: 2024-09-27T00:00:00.000Z
Sentiment: neutral
Topics: board-changes, executive-compensation
TL;DR
Aura Bio adds a director & tweaks exec pay. New agreements for CMO Diaz.
AI Summary
Aura Biosciences, Inc. announced on September 23, 2024, changes in its board of directors and executive compensation. Specifically, Dr. David E. Johnson has been appointed as a new director, and the company has entered into new employment agreements with certain officers, including an amended employment agreement with its Chief Medical Officer, Dr. V. Michael Diaz.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in board and executive compensation can introduce uncertainty regarding leadership stability and strategic direction.
Key Players & Entities
- Aura Biosciences, Inc. (company) — Registrant
- Dr. David E. Johnson (person) — Newly appointed director
- Dr. V. Michael Diaz (person) — Chief Medical Officer with amended employment agreement
- September 23, 2024 (date) — Date of earliest event reported
FAQ
Who has been appointed as a new director to Aura Biosciences, Inc.'s board?
Dr. David E. Johnson has been appointed as a new director.
What is the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is September 23, 2024.
Has the Chief Medical Officer's employment agreement been affected by these changes?
Yes, the company has entered into an amended employment agreement with its Chief Medical Officer, Dr. V. Michael Diaz.
What is the principal executive office address for Aura Biosciences, Inc.?
The address of the Principal Executive Offices is 80 Guest Street, Boston, Massachusetts, 02135.
What is the company's telephone number?
The company's telephone number, including area code, is (617) 500-8864.
Filing Stats: 1,168 words · 5 min read · ~4 pages · Grade level 12.8 · Accepted 2024-09-27 16:05:52
Key Financial Figures
- $0.00001 — nge on which registered Common Stock, $0.00001 par value per share AURA The Nasdaq
- $360,000 — d Ms. Elazzouzi's annual base salary to $360,000, effective on the Transition Date. Foll
Filing Documents
- d707178d8k.htm (8-K) — 30KB
- 0001193125-24-227950.txt ( ) — 151KB
- aura-20240923.xsd (EX-101.SCH) — 3KB
- aura-20240923_lab.xml (EX-101.LAB) — 18KB
- aura-20240923_pre.xml (EX-101.PRE) — 11KB
- d707178d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Aura Biosciences, Inc. Date: September 27, 2024 By: /s/ Elisabet de los Pinos, Ph.D. Elisabet de los Pinos, Ph.D. Chief Executive Officer